Immatics (NASDAQ:IMTX – Get Rating) and Sangamo Therapeutics (NASDAQ:SGMO – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings. Profitability This table compares Immatics and Sangamo Therapeutics’ net margins, […]
Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Rating) – Stock analysts at HC Wainwright lifted their Q1 2023 earnings per share (EPS) estimates for Sangamo Therapeutics in a report issued on Monday, May 1st. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will post earnings of $0.14 per share for the quarter, up […]
Should You Buy or Sell Sangamo Therapeutics Stock? Get The Latest SGMO Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.